文献速递慢性肾脏病血液净化与透析

MicroRNA调控在肾脏病临床结局中的作用

The Role of MicroRNA Regulation on Clinical Outcomes in Kidney Disease.
PubMed 文献 · Clin J Am Soc Nephrol · 2026-01-12

综述探讨MicroRNA(miR)表达随CKD分期、透析方式、左心室肥厚、血管张力及炎症变化,并提及不同血液透析方案下miR波动,但其机制作用未明;miR在体液中相对稳定,有望作为疾病监测与治疗干预的生物标志物。

要点

  • miR表达随CKD分期、透析方式及心血管改变而变化。
  • 不同血液透析方案可致miR表达波动,机制作用未明。
  • miR在体液中相对稳定,具生物标志物潜力。

核心结论

  • miR表达与CKD分期、透析方式及心血管改变相关,但机制作用未明。
  • miR在体液中相对稳定,有望成为疾病监测与治疗干预的生物标志物。

研究设计与样本

  • 综述,检索范围未在摘要中报告。

主要发现

  • miR表达随CKD分期、透析方式、左心室肥厚、血管张力及炎症变化。
  • 不同血液透析方案下miR表达有波动,但是否机制性贡献临床效应未明。

临床怎么用

  • 可关注miR作为CKD透析患者疾病监测与治疗干预的生物标志物潜力。

局限性

  • miR表达变化是否机制性贡献临床效应尚未解决。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

MicroRNAs (miRs), small noncoding RNAs that regulate gene expression post-transcriptionally, have been shown to vary in their expression throughout CKD stages, dialysis modality, alterations in left ventricular hypertrophy, vascular tone, and inflammation. In addition, fluctuations in miR expression have been reported with various hemodialysis regimens, although whether these alterations contribute mechanistically to the observed clinical effects remains unresolved. The relative stability of miRs in biologic fluids offers an opportunity for the identification of biomarkers for disease monitoring and assessing for therapeutic intervention. We will review the current understanding of miR regulation within the context of dialysis, to better define the molecular impact of conventional and intensive hemodialysis and guide the development of targeted strategies to mitigate CKD-related complications.

来源:Clin J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Alberga CA, Billia F, Chan CT, et al. The Role of MicroRNA Regulation on Clinical Outcomes in Kidney Disease. Clin J Am Soc Nephrol. 2026. PMID: 41525147. doi:10.2215/CJN.0000001002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。